Healthcare Momentum Builds: Apollo Hospitals Poised for 2–4 Month Rally
Show more
Show less
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
31 minutes ago
- Time of India
Court orders hair transplant clinic to pay Rs 6.3 lakh after complainant sees no improvement
The New Delhi District Consumer Disputes Redressal Commission has directed DHI Asian Roots, a private clinic, to refund Rs 5,01,000 and pay additional compensation after finding it guilty of performing a hair transplant procedure without a valid licence or government approval. The order was issued on May 22, 2025, following a complaint filed by a patient who alleged lack of results and unqualified medical staff, a TOI report stated. Commission highlights lack of licence and medical standards The commission observed that the clinic, a unit of SPA Yoga Private Limited, did not produce any government authorisation to perform modern scientific hair implantation procedures. It also failed to show approval for employing qualified doctors. The bench, led by president Poonam Chaudhry and members Bariq Ahmad and Shekhar Chandra, stated that conducting such medical procedures without proper licensing and expertise amounts to unfair trade practice. The bench said, 'It is essential that medical procedures are conducted only by qualified professionals holding valid licences, and in properly registered clinics that comply with established medical standards.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World Click Here Undo Refund, compensation, and cost awarded to complainant The commission ordered the clinic to refund Rs 5,01,000 to the complainant. Additionally, it directed payment of Rs 1,00,000 as compensation for mental harassment and Rs 30,000 towards litigation costs. The complainant had undergone three sessions at the clinic but reported no visible improvement in hair condition. The commission noted, 'Despite the complainant undergoing three sessions, there was not even 1% improvement. The clinic failed to provide any explanation for the lack of results.' Live Events Complainant raised issue of unfair trade and unqualified staff According to the complainant, the clinic assured hair regrowth or replacement under the supervision of expert doctors as mentioned in its brochure. He alleged that the clinic employed unqualified staff and carried out procedures without proper medical licences. Despite paying the full amount in 2013, he did not see any results, which led him to file a complaint. Clinic claimed procedures were informed and professional The clinic defended itself by stating that the complainant was made aware of the pros and cons of the transplant procedure. It argued that results varied by individual, and that the procedures were conducted in a professional manner, including additional work at the complainant's request. The clinic maintained that the patient's dissatisfaction stemmed from impatience and not following medical advice.
New Indian Express
35 minutes ago
- New Indian Express
Medi Assist Healthcare buys Paramount TPA for Rs 312 crore
MUMBAI: The Bengaluru-based third-party insurance service provider Medi Assist Healthcare Services has acquired 100% stake in the rival firm Paramount Health Services & Insurance TPA for a total consideration of around Rs 312 crore. This acquisition marks pivotal step in Medi Assist's continued growth strategy, reinforcing its position as the country's largest health benefits administrator. The transaction adds Rs 4,000 crore of health premia under administration to the only publicly traded company in this segment in India, Medi Assist said in a statement on Wednesday.
Hans India
36 minutes ago
- Hans India
Sensex, Nifty end lower as investors turn cautious over Trump's tariff deadline
Mumbai: The stock markets ended lower on Wednesday, as investor sentiment remained cautious due to US President Donald Trump's firm stand on the upcoming tariff deadline. The nervousness led to a risk-off mood among investors, pulling the benchmark indices lower. After rising to an intra-day high of 83,935.29, the Sensex lost momentum and closed at 83,409.69, down 287.6 points or 0.34 per cent. The Nifty also declined by 88.45 points or 0.35 per cent to end the day at 25,453.4. "Mixed global cues, particularly ahead of the impending tariff deadline, are driving investor caution,' Vinod Nair of Geojit Investments Limited said. 'Market attention is gradually shifting to crucial Q1 earnings, which have high expectations,' he added. Nair added that the underlying trends such as robust macroeconomic fundamentals and increased government expenditure continue to support market resilience. Among the Sensex stocks, the biggest losers were Bajaj Finserv, L&T, Bajaj Finance, HDFC Bank, and Bharat Electronics. On the other hand, Tata Steel, Asian Paints, Ultratech Cement, Trent, Maruti, and Sun Pharma were among the top gainers. Broader markets followed a similar trend. The Nifty Midcap100 index ended down by 0.14 per cent, while the Nifty Smallcap100 index slipped 0.41 per cent. Sector-wise, Nifty Metal, Consumer Durables, Auto, IT, Pharma, and Healthcare managed to close in the green. However, Nifty Realty, Financial Services, Bank, Oil & Gas, and Media dragged the overall sentiment with losses. The total market capitalisation of all listed companies on the NSE stood at Rs 5.35 trillion. Meanwhile, the India VIX, which measures market volatility, eased slightly by 0.66 per cent to settle at 12.44 points -- suggesting some cooling off in investor nervousness despite the day's losses. Gold traded in a narrow range as market awaits key US data releases. Comex Gold moved between $3327 – $3340, while MCX Gold traded between Rs 97,000 – Rs 97,400. 'The prices expected to remain in the broader range of Rs 96,500 – Rs 97,850 as participants price in potential dollar weakness and upcoming US data, including Non-Farm Payrolls (NFP), ADP non-farm employment, and unemployment figures,' Jateen Trivedi of LKP Securities stated.
